Company: Roche

Ticker: RHHBY

Please note that the webinar is being recorded I would like to inform you that all participants on listen only mode. During the call.

After the presentation there will be a question answer session you're invited to send in questions for this throughout the entire session using secured a functionality and soon in addition to that you May also ask you about your hand to address your questions traveling for participants joining via phone to raise your hand, just online on their phone style pass when you're done get selected to ask the question.

Please follow the instructions from the phone and press star fixed on mute yourself.

One last remark if you'd like to follow the presented slides on yearend as well please feel free to go to the worst outcome slash investors to download the presentation.

At this time, it's a pleasure to introduce you to Thomas Unica COF group, Mr. Silica the stages here.

Thank you very much and good morning, good afternoon and good evening.

Really really excited to share with you the updates for the full year, because we had an amazing fourth quarter not only in terms of financial results, but also in terms of pipeline use.

So let me get started on the normal overview slides.

So group sales in two.

<unk> 2025 grew with 7%.

Pharma, 9% diagnostics, 2% again this was due to the China health care pricing reforms without that diagnostics actually grew 7% last year.

Very strong operating performance with the core operating profit of.

13% and are cooperating margins plus one nine percentage points and core EPS plus 11%. So you may ask what's the difference between EPS and op why is there a deceleration. There. This is basically mostly driven through higher taxes.

On the full year LOE impacts that we had the impact of about $700 million.

Not really to the exciting parts.

We had truly an outstanding Q4, when it comes to pipeline news flow.

From a regulatory perspective, EU approval for <unk> in lupus nephritis U S and EU approval for <unk>.

Cut solutions third line plus Follicular lymphoma.

And U S filing for tiered restaurants in post CDK I E. Our positive hertz negative metastatic breast cancer.

Now I'll come the many positive readouts that we have.

Phase III.

Intrepid and finance so two positive studies <unk>, one and <unk> the other one in RMS.

Our positive phase III study just already this year in spring and <unk>.

Positive phase III, Lydia Jessica study in adjuvant ER positive <unk> negative breast cancer.

A positive phase III P S guy in the us and a positive phase III in <unk>.

And another positive phase III, cassava, Nossa <unk> and.

And positive for phase two in cities 388 in obesity and I know Theresa will go through a lot of these details with you, but you can see with very very busy news flow and I think theyre more exciting things to come also this year.

On the diagnostics side regulatory approval of the Lexus.

Dengue tests.

Matt will talk about that the Cobra Speedy CV test and also the mass spectrometry extension of our menu so exciting launches there as well.

You slow hits in 2026, we are awaiting the second spin of Britain of study in RMS We are awaiting a person of euro so that youre desperate in first line <unk> positive <unk> negative metastatic breast cancer, we have other studies reading out in the fall I.

<unk>, but also for Dave Arista K Ras.

Medicine and further inland to me.

So again, I think very exciting and we have a number of phase II readouts coming so it could again be a very busy year in terms of transitions from phase two into phase III and of course.

Everyone.

He's talking about it.

Exploration sequencing solution and we promised it for many years now here. It is so I'm super excited or supposedly that we're now coming with this very exciting solution to the market.

Yeah, I think it will cause a couple of waste in the market.

Now.

Let me go through the growth rates and I don't think I have to cover too much on the left hand side, but what you can see on this slide is that we have consistently strong growth in the last two years and even before that when we have to wash out of COVID-19 tests and the medicine, we had a good underlying growth so.

We always said we will deliver.

And we delivered.

Now on the 2025 pharma kept growing at 9% diagnostics. We did have the health care pricing reforms impact in China without that diagnostics was also have been growing consistently instead of 7% over this time period.

Again here, we just look at the full year, 9% growth again by the Pharmaceuticals Division, 2% by diagnostics again without the China effect, it's 7% and the Roche group has 7% growth.

And this is really driven across our entire portfolio.

Diagnostics I already explained and I know, Matt will go into that further.

But by a small we have continued strong global growth. We do expect that we will see even more uptake in the next year when it comes to the U S market now that we are also supporting more on the copay assistance foundations and Teresa will go into that.

Also OXXO there keeps growing significantly because either we have now launching.

Lupus nephritis, but you will see also the other indications really contributing to the growth in this business.

I'll call it you're growing well at 6%.

Professional we're now a global conversion rates above 50%.

The century, returning to low single digit growth of sensor growth driven by U S and Japan.

On the hematology side, probably be strong now we are reaching a U S patient share of 76% Callaway's consume your growth is driven by our second line plus launch and third line plus D. C. L strong sort line growth in Follicular lymphoma. So you can see also in the bulk of our franchise we saw.

Now a strong uptake of the sub cuts a solution as we also discussed and Arista as the leading SaaS solution.

And medicine now with more than 21000 patients on treatment.

Okay.

So overall, we have achieved the upgraded guidance.

On mid single digit sales growth, we had 7% and you may remember in the Q R E.

I our call in Q3.

You asked why are we not upgrading the guidance on sales and my answer was because 7% is still mid single digits and we delivered 7%. So we delivered on what we also communicated.

On core EPS, we upgraded the guidance from high single digits to high single digit to low double digits.

And why did we do that because we already knew that we would land in the double digit range. So we wanted to include it in that range and that's why we upgraded it at the time and we further increased the dividend in Swiss franc. So I can say, we for the second year upgraded the guidance during the year and we ended up on the upper end of this.

Two guidance is every time in 'twenty, four and 'twenty five.

Yeah.

Now what's super exciting is the growth outlook and the growth outlook has fundamentally changed based on some of the phase III readouts that we've seen in Q4.

So your desk strengths.

Search has had two positive readouts.

One with the Bureau, and the second one was the idea that you are reading out early we expect it to readout only next year, but based on the very significant results. It read out earlier already this year.

We're now waiting for the person Bureau data, but we clearly see that we have a very active and very good molecule in hand, not only is he going to replace the standard of care and it's going to become the new backbone.

Fields.

But it's so safe and.

And tolerable that we do believe that this will become the standard of care.

Bruce Nip in M. S. We had two positive studies here in RMS and then P. P. M. S. N. No Teresa will go into that we're still waiting for the second defend hence one study in RMS in order to be able to file. This you will see the data in not too distant future, but again, we are very excited with the data that we have.

Scene.

Because either the same we've had already positive data in lupus nephritis now we had the two more additional phase III data again, something that will give us momentum in the midterm.

On the Mickey part and in spring, we had two trials each and each of the two trials, we always had two arms and two different doses.

In one trial in both of those it was fully positive trial in the second trial, one dose was positive the other one was negative.

Now this was always a very close call and based on the conversations we had with the FDA. We do believe that the FDA will support filing here.

So this is the midterm and in the long term. What's also exciting is that we had 10 enemies.

Moving into phase III.

That's a record for US we've never had 10 nanometers moving into phase III and these are all enemies with substantial revenue and patient impact attached to them.

Now.

We know what the other part or topic. That's on your mind is our agreement with the U S government.

Now the agreement we reached with the U S. Government is not an L. O I, it's a contract with a U S government and based on this contract with the U S government, which has terminated for the next three years, we get an exemption from terrorists.

And we get the exemption of the demo project.

In return, we agreed to the Medicaid rebates in some of our portfolio.

We agreed to the encouragement of other wealthy nations to reward the biopharmaceutical innovation and to pay their share to contribute to innovation.

And we also supported the direct to patient medication access with <unk>.

Our influenza portfolio, so fluzone and tamiflu and also future medicines with which we can go direct to patients.

Also we agreed to invest in the United States 50 billion over the next five years. This includes R&D and PP&E investments.

And for example on the Red dots on the right hand side, you can see where these investments are happening in North Carolina Holy Springs, We are investing 2 billion in manufacturing for CVR M portfolio.

In Indianapolis It we're investing in CGM manufacturing and in Boston, We are investing in our research hub.

As well as we're going to invest more in genentech in San Francisco, but we already have a very strong manufacturing and R&D network president in the United States.

Now, it's all about delivering on the next innovation cycle. So I think we have a good growth momentum. We do believe we can sustain the good growth momentum and how do we keep that beyond 2030.

Well one is we've made substantial progress on our initiatives in order to prepare the company for future success for the last three years, we've been talking about high performing organization about delivery and about execution and I do believe we've delivered on that.

We've introduced a bar so that we focus on those medicines with the highest impact we have an intentional focus in terms of P. A's and also entered and disease areas and we look at the portfolio as our overall investment portfolio with certain risk and reward profile that we want to balance to have.

Our rights portfolio.

We're expanding into new technologies, not only in dire, but also in pharma and we're implementing AI across the value chain.

And we've made good progress in R&D now more than 60% of the enemies of post bar, 66% of the late stage projects have pest and disease potential we want to get to 80%.

And 60% more average peak sales pipeline project, if you actually take not end of 'twenty. Three if you take it end of 'twenty two it's even higher than the same for the total portfolio value.

Since the end of 'twenty three it's about 45%. If you look at the end of 'twenty, two as a comparator where more than 60% higher and this is a risk adjusted value.

So we do believe we've made a significant move when it comes to our pipeline in terms of higher rewards and also manage the risk.

We have a strong on market portfolio.

We have great readouts that are going to help us sustain our growth, but we have many many enemies that will read out before the end of this decade and many of them can be significant contributors to the sales of our company.

And here you can see the prioritization that we have done over the years in our portfolio.

Taking out high risk low value projects, and adding higher value projects with very strong data as a foundation and that gives us more confidence into phase III.

And this has resulted in a significant shift in our portfolio value as mentioned this is year end 'twenty three as a base.

Baseline if you take you in 'twenty two it's insignificant.

And on the diagnostic side.

As I mentioned, we have the experienced they've been experiencing the headwinds in China from the Heska pricing reforms.

These headwinds would become a lot less in 'twenty to 'twenty six it will be gone in 2027.

We will continue to grow significantly this year, we expect mid single digit growth, but then back to mid to high single digit growth in dis.

Products that you see here can each contributes additional 1 billion when it comes to sales for you.

And again very excited about the sequence of that's coming.

Now let me go through the outlook.

For 2020 six we again have an exciting year when it comes in terms of pipeline Readouts.

But then after that 27 28 29, we will have many different enemies that we'll have phase III readouts.

In 26, I just want to highlight a couple.

The press of your put your restaurant.

If in the Brutes Nip I Tobey Dave ERISA.

A number that.

Can also continued to drive our growth in the next years.

And of course, we have a number of phase two readouts in obesity two of them already have been positive. This year. So we had a very good start so the year end it well in terms of Readouts and the year started well in terms of Readouts. So we're very positive in terms of the momentum that we have and that we can continue this momentum.

And these are the 19 medicines that we can launch by the end of the decade.

Now, it's clear that not all 19, ultimately will make it.

But these are really substantial contributions that they can deliver to the future business of our company and two patients out there. So I'm very excited about what's ahead for us.

Now, let me talk about the 'twenty 'twenty fixed guidance.

And group sales again, we expect mid single digit sales growth in core EPS high single digits core EPS growth and we do believe that we can continue to further increase the dividend in Swiss francs.

With that and over to Theresa.

Oh yeah.

I think well.

No no.

Yeah, welcome from my side as well.

As Thomas has a great pipeline progress.

And it really then combined with great financial results I think that's really a that's a great setup and thanks to the whole Roche team for delivering that so let's go into the results right away.

And here's the overview and I will focus on the right hand side, so really the changes in concentrates.

Sales plus 7% [noise] met entry reached that would go into this 9% of the pharma side, 2% on the die outside as said I think.

So on the diet side with the impact from China met will a real highlight this the cooperating profit plus 13%. So you see really good cost containment, but at the same time, we have invested where it really matters.

I will lead you through this and then Thomas mentioned at a slower momentum on the core net income in the core EPS, yes, driven by a higher tax load.

The 600 million 579 million more Texas that.

If you had to buy average broad the momentum a little bit down I address net income up 58% and and you know where it comes from comes from a base effect from last year, and we had to goodwill impairments accounted for 3.2 billion negatively.

If you adjust for that I think it would be a plus 20%, which in my opinion mirrors very well the operational performance.

Now I come to the cash flow and be cutting out debate quite a bit about the cash flow I think you'll see it a 16.2 billion down from 'twenty to 'twenty 0.2 1 billion.

Let me say here, we had really a very strong December when it comes to sales and quite an increase in accounts receivables. They will convert into cash so automatically what I'm, saying I expecting quite a strong cassia 2026.

The other piece here is internet trade working capital inventories, we had the situations that we have to deal with the tariffs. So we brought inventories up.

A little bit that contributed to this and loss of lease we have invested more into intangible assets roughly 600 million I come to this but I think that explains the number very well as said I think we will recover quite well.

On the cash flow side in 2026, let me say I will also highlight this net debt came down at the same time I will lead you through this.

Good I think when you look at the bridge here for the sales and concentrate 7% up as you can see when you go from the left hand side to the right hand side. There is a plus 2% because we have the currency impact in which is quite significant with Miami on this five percentage points, let me focus on the middle <unk>.

You see pharma and the loss of exclusivity of minus 745 million in total at plus 9% as mentioned and then you see the situation in dire and where we have a 7% growth excluding China and we have then an impact of minus five fund at 979 million coming really from.

<unk> kept pricing reform in China, which a means of minus 24% of sales in China itself.

Good with that lets go through the P&L I.

I talked about the sales growth.

Other revenue I think on one hand, we had a lower milestone income compared to last year minus $87 million, but we also had higher royalty income that by this is very very stable.

And really looks good cost of sales both divisions increased their cost of sales by 7%, but with very different dynamics I think really in a from a volume point of view and pharma plus 13%. So very very clearly I think here driver for the plus 7% growth on the on the cost side I think that gross was also live.

Supported by by royalty expenses.

And the dire division plus 4% on the volume side compare now to a plus 7% growth on the cost side. So what is that triggered by well very clearly the health care reform plays a role here, so China once again, and but also higher costs related to placing of machines, which suddenly fuels, our future growth of diagnostics sobell invested here.

And we had certainly investments into the new technologies like CGM, Nomura etcetera, and last but not least we had a tariff impact you know on the diagnostics side of 64 million half year impact. So that's also something we potentially have to deal with in 2026 cooperating profit up a 13% a nice margin.

Increase when you look at the margins itself I think really in constant rates overall, plus 1.9 percentage points.

For the group.

You'll see a nice progression on the pharma division, you'll see a decrease of minus 1.1 percentage points in C. R. On the diagnostics Division side, which is explainable given you had that here a significant portion of the sales in China went away.

And when you look at the core financial results Ah and really here Interestingly I think really in you can see our we have an increase and you look at Swiss Springs, we have a decrease.

And I think really what that speaks for as well the U S. Dollar this week hurts us a little bit in the P&L, but helps us with the financial result town. That's that's one conclusion here you see the equity Securities. This minus 88 I see the market has recovered, but we have some investments in the Roche venture fund, where we wait for data so hopefully a better year ahead.

Net interest income we had less cash elevate available led to less income here interest expenses was plus 69 million concentrated would be rather flattish.

But but let me let me say he has suddenly the weak U S. Dollar helped and then we have really here other and these are predominantly less hyper inflation impacts compared to last year, so with that let's go to the tax rate.

Thomas mentioned it I mentioned it a already let's focus on the middle of the slide first you'll see really the effective tax rate full year 2024 exclusive the resolution of tax disputes 18, 1% and then you see really the effective tax rate full year 2025, excuse me to the resolution of tax dispute was 19 point.

5%, So you really see the.

The increased momentum here Bose, yes, yeah, we're really mitigated by the resolution of tax disputes in 2024 that was a positive of $263 million, representing the minus 1.4 percentage points and in 2025, it was a lower effect plus $185 million in concentrate.

<unk> yeah.

Resulting in minus <unk> nine percentage points, leading to the effective tax rate full year 2025 was 18.6% well for 2026, I think we will hover more to a 20% tax rate.

Core EPS on the core EPS side. This is the bridge here I think for me. The most important point to say is it's driven by operations to increase in core EPS is driven by operations, Yeah, and I think that's nothing better to say here and look I think the practice poses a you've seen the P&L I think less income you are coming from that.

Financial income and expenses are negative and concentrates the slides and concentrates that's a negative is roughly $60 million and then effective tax rate changes asset. This is once again mentioned increase on the tech side, you know that we have seen here so operations, whilst a major driver all other effects on that slide worked against us.

When you look at noncore.

And the IRS income I've mentioned, the iron Francine come see it on the right hand side, plus 58% cooperating profit I've mentioned as well as plus 13%, perhaps two points to mention on that slide one is the global restructuring fence. Your series of restructuring charges have increased by roughly 300 million I would argue that's a positive because it gives us savings in the future.

And then I think you see the impairments of intangible assets as mentioned not a lot of impact in 2025.

In 2024 was $4 6 billion negative if you're an enormous impact very much driven by the two goodwill impairments for spark and flight iron accounting boasts yet to get up a.

Minus 3.2 billion.

With that let's go to the cash and he is the story.

When you look at the left hand side, a 20.2 billion I've mentioned that already in 2024, and then you see in concentrates full year 2025 was 17.7 billion well you see really when you go back to the left hand side are the.

Operating profit net of cash adjustments I think that's the positive momentum coming from operations really positive and then you see the net working capital movement and out of that net working capital movements minus 2.2 billion comes from net trade working capital that said predominantly driven by accounts receivables let me.

Mentioned here that has nothing do with extended payment terms for certain product and nothing to do with this revised Moe. This is really we have four especially pharma buys more payment terms for a longer period for the last couple of years and we have not changed them. So this is really because we had a strong December and that brought the accounts receivables up we have the IV are higher.

Inventories on the pharma side that explains the minus 2.2 billion, we have the investments in PP&E placements in diagnostics for the positive side investments that we have done and then we have the investments in intangible assets. The increase of 645 million very much driven by sealant and the deal. We have done there then foreign exchange kind of it.

In was minus eight percentage points quite significantly leads us to an operating free cash flow of $16.2 billion.

Well I think when you look at the margins I think that tells the same story here. When you look for it yeah I cant just really point back to the to the fact that we will recover in 2026.

Now.

When I talk about cash I have to talk about the net debt development and that in total.

As well.

<unk> said I think interestingly.

When you look really at net debt at the end of 2024 was minus 17.3 billion. If you compare that on the right hand side, which the net debt position at the end of 2025, we have reduced by 1.1 billion. So I'm I'd ask yourself, okay. The cash flow. It was not so strong how how is that possible invest less especially on the M&A side.

We didn't I think that the numbers I'll be a BD on the on the lower part of the slide as you can see on the right hand side you see what we've invested in intangible assets and an M&A is pretty equal yeah.

$4 6 billion in 2024, and even more in 2025 was $5 1 billion.

One driver here is.

Is the weaker U S dollar and.

And you see it really when you look really on this bar minus 10.7 billion dividends MNI and alliance transactions and other so as the currency penetration point with plus one 8 billion that is a major driver and helps us on the debt side by the way we have decreased gross debt by $3 1 billion and suddenly.

70% of our gross debt is in U S. Dollar the U S. Dollar helps in that sense to bring the debt down at least when we report in Swiss francs.

Good with that quick comment on the balance sheet I'm not too much to say when you look right on the edge on the left hand side, where we have the assets I think cash and marketable securities went a little bit down nothing to mention he had paid the dividend all of that but.

When you look at other current assets well higher trade receivables as mentioned already mostly coming from the pharma side and when you look really at the non current assets that was driven by higher intangible assets of 4.1 billion, mostly acquisitions accounting for plus 2.5 billion on the right hand side, you see the liabilities and the equity.

Current liabilities increased mainly due to the higher accounts payables and bank credit us some loans here and the non current liabilities decreased slightly due the decrease in long term debt I've mentioned, a 3.1 billion already.

Leads us to an equity increase quite nicely and now an equity ratio of 38%.

Yeah.

Good leads me to the currencies well, yeah, I think really the volatility is certainly disturbing and the weak U S. So that's something we're fighting against them you see really the results for the full year and minus five percentage points on sales and minus eight percentage points on cooperating profit of minus seven percentage points on core EPS.

Yes.

To be honest, if you apply today's rates that would be basically the same picture for 2026, if we keep all that rates from today until the end of the year 2026. So I think it would be basically the same impact when you compare it year end 2025, and you keep these currency rates stable.

Until the end of 2026, you see it really on the Bulks down low the impact would be minus four percentage points on sales and minus six percentage points on core operating profit and core EPS. This topic remains in 2026.

Good core EPS.

I think really we wanted to set the base right for you know for the core EPS and what is the starting point because we have currency effects in there in the core EPS. So let me lead you through this you'll see on the left hand side, the 19.46 Swiss francs per share as reported.

And then I think really be adjust for all points III seven Swiss francs, yet to get to the 19.83.

Swiss francs per share, which would be the starting base for your calculations into solves an awful if you like for the core EPS in 2026. So let me explain now the old points III seven Swiss francs.

And what you see here. These are the exchange rate effect. This is a result of dividing the 2000 and twenty-five currency losses of minus 273 million Swiss francs, as well as the 2005 or five Tucson and twenty-five losses on net monetary position in hyper insulin I appreciate economies of minus 48.

Million. This is shown in note four of the consolidated financial statements on page 64. So on page 64, you'll find that these two numbers net of taxes and noncontrolling interests by the number of diluted shares you off $803 million and this number is outlined in note 20.

Nine of the Finance report on page 126, just to confirm that.

Which is I think quite a positive because it sets the higher bar for us so to say, so hopefully a little bit of a positive for the projections for 2025. He asked the guidance again Thomas has alluded to it let me mention two at the loss of exclusivity impact that we have estimated or S. E that we expect of roughly 1 billion.

For 2026, so relatively narrow yet to what we had for 2025 and well in line between the one and one 5 billion that we've indicated to you that we will have on an ongoing basis and with that I have the pleasure to hand over to TV.

Thanks Alan.

So I hope.

I'm going to hand, it back to Alan head back to me at Televisa.

Yes, it's hard to try to bring it to you, but let me make a last comment here.

Have a we have a change in our income statement presentation for 2026.

Let me say very clearly yeah. It has nothing to do with the group in itself. So really when you look at sales group cooperating profit and the core EPS the metrics are unaffected.

This topic is between corporate and the divisions and basically what we are doing is we are centralizing the legal department, that's what that is.

What we're doing.

And that has quite an impact when you look at pharma, we reduced the SG&A costs in form of about $250 million roughly I think suddenly in concentrates which represents roughly half a percentage point in cooperating profit margin. So you should adjust for that in your calculations on the diagnostics side that.

Roughly $50 million less for the SG&A costs, which represents all points and four percentage points in the cooperating profit margin in C. R. Corporate equally then would increase by $300 million, Yeah, just to point that out as said for the group accounts nothing changed now this is between the divisions and corporate.

Just to remind you when you project your margins fall, but for 2026, especially for the divisions.

And now yeah, I have the pleasure to hand over to do is I'm going to move forward really quickly in case, they try and take it away from me again.

Now, let's jump right in.

So as Tom assured the group perspective, like you're a little earlier I wanted to provide some additional color on the key priorities for the pharma division starting with their focus on delivering the on market portfolio Q4, 2025 marks our eighth consecutive quarter of growth. So today's on market portfolio continues to deliver strong performance of 16 blockbusters across our five third.

If you take areas. We expect this momentum to continue until 2028 and thereafter, we expect that sales at becomes stable just fully compensate for generic erosion importantly, we do not expect the patent cliffs as Thomas mentioned now in the near term, we are expecting to deliver multiple key launches, which come on top of todays on market portfolio. This inquiry.

Cause either in immunology, Jerry best friends in breast cancer and in Britain and M. S. Then Niki bar in Nuomi and in spring with additional indications in both neurology and ophthalmology. We expect that these products are going to continue to extend our growth momentum until well beyond 2028. We are currently in the process of updating our mid to long term outlook and we'll be sharing.

That with you a little bit later this year.

And so while we're very excited for these upcoming launches. We are just as excited about the progress that we've made on our pipeline as Thomas mentioned through R&D excellence and rigorous application of the bar, we have successfully rejuvenated our pipeline with our posts by any means we have the potential to enter new disease areas like Alzheimer's and obesity and we aim to bring multiple.

New transfer transfer transformational medicines to patients.

As I mentioned that pharma day, Oliver activities are really driven by two key tenets discipline in the business and break out the science.

To put it in the business, we remain committed to keeping our costs at least stable and rigor in the science optimizing how we spend our R&D budget and applying our bar criteria to each and every asset progressing in our pipeline are entering it including from partnerships or acquisitions.

I am truly excited and confidence in the future if rmi delivering transformative medicines and sustaining our growth momentum. So now let's take a closer look at how this momentum played out in 2025, and we'll start with the full year sales.

So as you heard from both Thomas and Allen Farmer sales grew at 9% at constant exchange rates, reaching $47 7 billion Swiss francs. All regions are delivering strong performance led by our international region with 14% growth and overall, our volumes were up by 13%.

As Alan mentioned comp increased by 13% versus that 9% sales increase of the cop margin of 49, 2% a slight increase over last year clearly copco ahead of sales, which we mainly attributed to effective cost management, particularly in R&D, but I am going to drill down on the individual line items in a little more detail.

Other revenue and.

Other revenue slightly decreased by 1% with higher profit sharing income from the higher sales I think flex that in the U S, which was offset by lower income from our out licensing agreements.

Alan mentioned cost of sales increased 7% against a 13% volume growth.

R&D costs declined by 3%. This is mainly driven by savings in flat iron as well as some other operational efficiency that upper operational efficiencies, but let me say that this reduction it was very thoughtful and deliberate as it gives us the oxygen that we need for the upcoming C. D. R. M phase III trials SG&A costs increased by eight.

And this was primarily for two reasons it was driven by some investments in our growth drivers, particularly <unk> and <unk>.

And.

Sure, but also increased donations to multiple independent co pay assistance foundations as part of our broader corporate philosophy, Philadelphia Philanthropy strategy Genentech are doubled its donations to this independent co pay assistance foundations in 2025 versus 2024.

Our corporate giving strategy is focused on supporting the patients most in need across multiple therapeutic areas, including oncology neurology immunology and ophthalmology and we continually evaluate the strategy to ensure that it remains aligned to patient needs.

And finally, other operating income and expenses decreased by 43% and this is primarily due to lower gains on the disposal of products.

And so now let's look at our individual growth drivers. So as always first I have to comment on the graph. These are all absolute values and year over year growth rates are presented at constant exchange rates.

Full year, our top brands FESCO Xolair <unk> can lever up a buy sell and preliminary generated roughly $3 6 billion in new sales at constant exchange rates for the fourth quarter in a row Cisco is our number one growth driver with 48% growth closely followed by Xolair driven by the continued outstanding uptake in food allergy.

You'll also notice the strong performance and stuff like that and I just want to talk for a minute about that here, which is driven by the strong flu season that we saw in Q1 of 2025 in China. This may create a bit of a base effect for Cessna and Twenty-twenty sex, especially considering that we haven't seen a similarly strong flu season in China a share.

So now let's dive into our Tas starting with oncology.

Oncology sales increased by 2% to $15 3 billion Swiss francs, primarily driven by our hurts your franchise as I mentioned FESCO posted an impressive 48% growth in the global conversion rate keeps climbing we're now at 54% well on our way to our new goal of 60%. This of course also means that project conversion dofasco continues to impact for China sales, which used to be expect.

I can't find the growth continues to be driven by uptake in adjuvant breast cancer I'm looking forward to the her two franchise overall and as I've said previously previously we expect the her two franchise to peak this year at about 9 billion at 2024 exchange rates, followed by a steady decline through the end of the decade with the <unk>.

Solid tail of around 4 billion and that $4 billion is primarily a cisco about a billion for cat silo and a bit of A&P, we do not foresee a biosimilar in the U S. But forget out until the end of 2027 and let me also confirm again that we do not expect a cliff situation for the hurt your franchise.

It's healthy we see good lunch momentum in a first line P&C a kinase.

HR positive breast cancer population and we expect to phase III Readouts. This year it with another 121 and $1 22, which could enable further indication expansion, but of course, the highlight of Q4 with a positive phase III of the Dara result figure that strength I am going to cover this in more depth on the next slide but let me give you a few quick updates.

Gary just aren't in general.

We presented to the library data at San Antonio Breast and we have already filed their results with the FDA that happened at the end of last year, an EU filing is expected for 2026. Therefore, we expect a very U S. Approval later this year, but Dara results will be filed with the U S and EU regulators this year and the.

First half of this year, we expect the readout of perseverance and first line I E are positive of her two negative metastatic breast cancer.

Moving onto centric to centric exited with exited 2025 with 3% growth in actually quite a nice Q4 for.

For 2020 six we expect low single digit growth for to centric driven by the positive studies that we started last year such as in 14, and small a small cell and bigger and it might be C anatomic and DMR colon cancer and.

And finally before I move to the next slide let me just briefly mention that we expect the first phase III readout for our K Ras G. C inhibitor either asset later this year.

So now let's take a closer look at the lit Darrin results for Guestroom.

So here the Jerry that's around like Arizona, and adjuvant <unk> positive her two negative breast cancer, which we presented last December as you can see if you're desperate presented demonstrated a statistically significant and clinically meaningful improvement and they said disease free survival versus standard of care of endocrine therapy, achieving hazard ratio of <unk> seven.

Let me emphasize here that this is the first oral sorry, I just had a superior I D F S versus endocrine therapy in the adjuvant setting and in terms of overall survival data is still immature, but clearly a possible positive try and for Gary desperate was observed with the habit hazard ratio of appoint 79.

Tiered restaurants safety profile remains favorable as we've seen in previously PV.

Ah studies and importantly, we saw a lower discontinuation rate with your desktop versus the comparator arm. This is a significant improvement in this setting and it indicates the improved patient experience on Gary that's right.

Pair to standard of care. So taken together. These results further underlying youre desperate potential as a next generation best in class endocrine therapy, and ER positive breast cancer.

To expand on this let me dive a little bit deeper into the Jared I start development program.

So now given the positive area and the Dara results. He just discussed and the upcoming Readouts. We're very excited for the future of Teradata strength, that's where it has the potential to replace standard of care of endocrine therapy, and ER positive breast cancer and becomes a new backbone of choice in the setting as you can see in the treatment paradigm on the left our clinical development programs, which are definitely it covers different lines of treatment in <unk>.

Scripps with the readout of personnel and first line expected mid first half of this year. Please.

Please note that they carry desktop plus CDK four six combination in madera relates to a single arm subsidy, that's still being evaluated that's in combination with a demo and we have also started a sub study in combination with <unk> as well.

As you would expect we are working at speed to complete filings and collaborate with regulators to ensure that this transformational medicine gets to patients as fast as possible and just to reiterate we have already fired in there we have already filed a ore in the U S and expect Madera filing in Q1.

Here, a desk and we also have a strong pipeline of potentially best in class molecules in breast cancer that give us the opportunity for numerous feature of combinations for instance, our highly potent CDK four two inhibitor, which may overcome some of the limitations of currently available C. D. K four six inhibitors and as I mentioned, we believe there is the possibility to become the new backbone of choice and are positive.

Breast cancer and is therefore, we're exploring many combinations with some of the internal assets as I just mentioned.

Additionally, our phone keeps ringing as we are getting calls from potential partners interested in combination studies with Jared Astrium.

We look forward to sharing future updates on our breast cancer pipeline with you in the near future, but for now let's move on to hematology.

He came out of the hematology franchise delivered strong growth of 15% and 2025, achieving $8 6 billion Swiss francs himself and lever it closed the year with strong growth of 12% driven by increasing adoption in the non inhibitor patient population for.

For 2020 six we expect low single digit growth and that's partly driven by competitor launches, which are anticipated later in year <unk>.

<unk> gross momentum continuing into 2025, reaching U S patients, there's a 36% in first line there'll be C. L. But in fact, we reached two significant milestones with pulling me last year first it is now the most prescribed regimen for Ipi two to five patients in the U S and second we have officially hit more than 1 billion Swiss francs in sale in the first line setting.

Yeah.

Shifting to Colombian law semi our C D 20th C. D. Three bi specifics launch performance remains on track for Colombia in third line plus the L. B C. L. With second line D. L. P. C. L. Lunch is gearing up for launch Emil We're happy to report that the subcutaneous formulation has been improved in both the U S and the EU and just a reminder that that new formulation.

[noise] reduces administration time from hours down to actually under a minute. Additionally, we expect two key events Frameless EMEA later this year, we expect U S approval for Eylea in Sydney, a plus plenty in second line there'll be C. L. Based on the positive fundamental results and we expect the readout for the phase III Celesio in second line plus Follicular lymphoma.

So now let's move on to neurology.

Our neurology franchise achieved 9.8 billion Swiss francs and sales in 2025 with a strong growth of 11%, Oklahoma continues to have good momentum delivering 9% growth globally and crossing the 7 billion milestone in annual sales were excited to see the increasing growth momentum of our subcutaneous formulation notice.

Oh in the U S. In Q4 more than half of global Okra Mis growth was driven by the sub cut formulation and importantly in the U S and many other early launch countries roughly 50% of Novo patients are naive to know Chris.

This represents that acceleration that we've been talking about U S. Uptake continues to be driven primarily by community practices, which emphasizes how does the novo is actually expanding the addressable market and can help overcome health care system restraints like IV passively IV capacity limitations overall, we now have more than 17500 patients on OCA.

Mobily and that's roughly 5000 more than we had at Q3 for.

For 'twenty 'twenty six we expect to hit high single digit to low double digit growth for OCA of us and as a reminder, we upgraded our peak sales expectations for <unk> for the Alkermes franchise to 9 billion CHF by 2029. This includes $10 billion of Swiss francs, and incremental sales from sub cut but of course, there's also going to be some switching from IV to <unk>.

Staying with the MS franchise, you've seen the exciting news regarding the positive three results for Penn in Britain, and we're going to cover that more on the next slide but for now let's take a minute on that.

Global rollout of the tablet formation continues and we see great pick up from that as well as very positive feedback from the patient community as Thomas mentioned this remains the leader in SMA.

Quick note that Q4 procurement Q4 performance for ever see in international was boosted by a tender related buying patterns, but we are still expecting double digit growth forever I see next year.

Earlier. This week you saw positive data from <unk> in D. M. D. We continue to believe in the part of risk benefit profile and the ambulatory DMD population and more than 1050 patients have already been treated globally in the setting. Furthermore, the latest three year data from embark shows the durable efficacy and slowing of disease progression for ambulatory DMD patients treated with <unk>.

Yes.

We are working with EMA continually to find viable path forward for EU patient access here.

I'll quickly stopping over probably a quick update here, where we have achieved both F. P. I for the phase III study as well as we have been able to materially accelerate site activation. So are a number of months ahead of schedule.

With the prostate trial, which is great news for patients and let me close quickly by speaking a little bit about and spring and multi day somebody. If you are not aware is a rare antibody mediated autoimmune condition of the central nervous system, which causes inflammation of the brain optic nerve and spinal cord the phase III setting meteoroid readout positively.

We're looking forward to presenting that data at an upcoming medical conference. Later this year, we expect to file these results with the U S and EU regulators in 2026, and this additional indication could unlock an upside of approximately 500 million for spring.

Now as promised let's take a little bit of a deeper look at set up right. Now we are very excited about the positive phase III readouts for Fannie <unk>.

It's been trapped in N P. P. M. S. N sand has two in RMS with the fed has one readout expected Manhattan to share. These results makes ibrutinib the only be TK inhibitor with positive phase II results in both RMS and P. P. M S and it has the potential to be both first and best in class and our M. S. N. P. P. M S, which would also make it the first and only high efficacy.

Oral treatment for both relapsing and progressive multiple sclerosis.

Let me see if that in Britain name as an opportunity to increase high efficacy treatment rates amongst MF patients and expand the footprint of our franchised okra missing out of sub cut have brought transformational impact people living with M. S and we believe that in Britain. It has the potential to be that next transformational medicine for these patients.

Let me also briefly remind you that then in Britain. It is differentiated by design from other PTK inhibitors. It is the only non covalent binding PTK in phase III development for MF and has a highly optimized PK profile that allows it to reach its target including in the brain. So stay tuned for the fan hands one readout in half one and until then we look forward to presenting with intrepid results in P. P.

EMS at actions, where we are also inviting you to attend our IR event on the ninth of February.

So with that let's move on to immunology.

Our immunology franchise grew at 12% at constant exchange rates and reached $6 7 billion Swiss francs and sales Xolair has strong growth momentum continues driven by uptake in food allergy in 2020 five we achieved 32% growth in sales of 3 billion Swiss francs.

We're also happy to celebrate our key Xolair milestone in 2025, which is more than 100000 patients have now been treated for food allergy since launch.

Regarding the 2006.

2026 outlook first of all are we expect around 20% growth.

This includes the impact of an expected first biosimilar entering the market in the second half of the year.

You will have seen that so there was selected for the latest rounds of Iran. Negotiations. So let me provide a little bit of extra information on this so there's inclusion on this list as you know does not change patient access our pricing at this time any potential pricing impacts applicable would not take effect until 2028 at the earliest.

The famous has got final guidance provides for the selected drug will no longer be subject to negotiation and will cease to be a selected drug if CMS determined that a generic or biosimilar has been marketed by November one 2026, and we do expect that a biosimilar for us although it will be launched before that date.

Our camera sales declined by 2% in 2025 as predicted we are now seeing increased biosimilar impact in the U S, which resulted in a 10% decline in growth and in Q4. This is aligned with all of our previous communications of an accelerating biosimilar impact in the second half of 2025, which will obviously continue into 2026.

Just like in Q3, because that is one of our key highlights for the quarter. Following the FDA approval in Q3, we achieved EUR prelim lupus nephritis, and we announced positive phase III readouts in both SLE and I N S. In both indications because either has been has first in class potential S. Early results have been submitted for presentation at SLE Euro in early March and the.

<unk> results have been submitted to WCS in late March both indications as a as I mentioned I think previously will be filed in the U S and EU later this year and I'm also very happy to share that the FDA has granted breakthrough.

RP designation for because I havent childhood onset idiopathic nephrotic syndrome, which as I N S. Based on the positive in short results and we are not quite done with cause iva just yet there's one more phase III trial, which is expected to read out in 2026, and that's Majesty and membranous nephropathy.

And as a reminder, we see up to a 2 billion Swiss franc opportunity for I guess, either in kidney disease, and just finally I'd like to mention the upcoming phase III readout for facts are sending IGN, which is expected later in the year now lets move on to ophthalmology.

Ophthalmology and grew by 10% achieving 4.2 billion Swiss francs in sales the buys low performance as you know was impacted by the contraction of the U S branded market and landed at 12% growth for the year, which is still quite strong.

<unk> mentioned this contraction previously and through 2025, we saw a decline in branded IV T market in the U S of about 15%.

The less the buys no continues to gain market share in the branded IGT market in the U S. In a crunch early launch countries globally and the U S. We now see that more than 60% of our buys no patient starts are from treatment naive patients and this further solidifies the business position as the standard of care looking forward, we would expect the U S branded market to gradually.

Over in 2026, and taking this into account we expect a growth acceleration in 2026, driven by the ex U S continued growth and U S recovery and.

In fact, as Thomas mentioned, there is a lot to look forward to in ophthalmology. This year, we have two potential new medicines entering our ophthalmology portfolio. That's then Niki bar and you let me, which is expected to be filed in both the U S. You and spring in thyroid eye disease will be filed in the U S. And we are currently considering ex U S file ex U S filings I'm with.

With the appropriate regulators now, let's jump into our C. D around pipeline, if there's one slide with a whole bunch on it but I am very happy to share with you. The key developments in our pipeline as well as provide a perspective on a very niche slow rich 2026.

So earlier this week, we shared positive a final phase two topline results at week 48 for the once weekly C. T 388 in people with obesity and this study 103.

For the efficacy estimate we achieved a placebo adjusted weight loss of 22, 5% as a reminder, the efficacy estimate includes patients who dropped out from further analysis of the effect size measured represents the true efficacy of the medicine test it.

For the treatment regimen S demand, we achieved a placebo adjusted weight loss of $18, 3%. The treatment regimen estimate reflects a more real world outcomes acknowledging the fact that not all patients will be able to adhere to treatment. In this case data after treatment just can take continuation either in the treatment or placebo arm are included in the analysis. So for example, it includes data from patients who discontinued.

New treatment early and have regained weight.

This is a question we received a number of times over the last week. So I'm just going to take another minute here to reiterate generally speaking the difference between the efficacy and treatment regimen estimates is usually driven by treatment discontinuation either due to patients on the active treatment arm, who regained weight after discontinuing treatment or patients on placebo.

Go on a weight loss therapy. After discontinuation there are many ways to potentially address this phenomenon in our future phase threes from a more flexible dosing regimen, which allows patients to stay on lower maintenance doses in case of tolerability issues due to the incentive of a long term extension to retain more of placebo patients, but these kinds of measures should serve.

To improve the discontinuation rate and eventually reduce the gap between the two last months and.

With that context, I should also point out that in most of the recent phase II trials in obesity market differences between the estimate is greater than 5% have been observed.

Let me also highlight two other key points in terms of the efficacy achieved in the study first we saw a clear dose dependent relationship on weight loss and secondly, and most importantly, we are pleased by the absence of the visible efficacy plateau at 48 weeks for the highest dose tested which was 24 milligrams.

Together. This clearly indicates that further weight loss can be achieved after 48 weeks and it gives us confidence in C. T. Three eight eights potential to deliver best in class efficacy for obesity in terms of safety and Tolerability of C. T 388 was well tolerated tolerated in the Tolerability profile is generally consistent with the increase in class the majority of gastrointestinal related.

Events were mild to moderate and total treatment discontinuation due to as an all arms were low at five 9% for C. T 388 versus one 3% for the placebo arm. Let me also highlight here as we received this question a number of times as well the discontinuation rate due to aes at the highest 24 milligram dose was similar to the total discontinuation rate.

Observed.

We look forward to sharing more detail on the phase two results with you at an upcoming medical conference. Later this year. Similarly to 388, we saw positive results for C. T 868 in phase two of our fourth study in type one diabetes and just like for C. T 388, we will show the final results at an upcoming medical conference in 2026.

So speaking of the outlook for the rest of the year, let's start with our phase two and phase III study initiations as a reminder, we announced for both C. T 388 N C. T 868 that we will move them into phase III development in 2026.

For C. T. Three eight we can now provide the first update the phase III trials for C. T 388 named <unk>, one and <unk>. Two are now scheduled to start in Q1. In addition, you can see that we plan to initiate the first phase two studies for Petro Lin tied and C. T 996, as well as our phase two combination study for C. T 388 with petrol the tide.

In addition.

We have a number of other C. The army that's scheduled for 2026, there are multiple phase II readouts to look forward to them. The four C. T 388, we have data for patients with obesity and with type two diabetes, which will come later this year. We also expect the first two a phase two readout for <unk> 99, six our oral G. G. L. P. One and perpetual then tied to.

Supreme One and two trials in obese and overweight patients with and without type two and finally, a move of our answers appetite combination data in obesity are expected towards the end of the year. So as you can see we continue to progress our feed your own pipeline at pace and we are excited to share updates with you throughout the year, So last but not least let's go to the next slide to bring US home here, we have the 22.

Six farm a key news flow, we start the year with four Green Checkmark, certainly a good omen for the year ahead, and we have discussed everything else on previous slides. So I wont go into more detail here for any of you who are feeling the lack of the 2025 years slow table, we have moved that to the appendix and with that I would say I'll give it back to Alan but it'll be crazy and I'll give it over to Matt.

While the wild Alright, Wild times, Thank you Teresa and good morning, and good afternoon, everyone. It's my pleasure to present, the full year 2025 Diagnostics Division financial results.

So with sales as you heard from Alan <unk> from Thomas sales and diagnostics were 13.8 billion Swiss francs, regroup, what 2% or 292 million Swiss francs, compared with 2024 at constant exchange rates, but as you heard from both Thomson all earlier, excluding the sales in China, which I would reiterate is our second law.

Largest market was impacted by health care pricing reforms the growth of the diagnostics business was 7%.

So now let me walk you through these results by each of our customer area. So.

Sales in our largest customer our core lab were flat again, driven by the previously mentioned health care pricing reform excluding this effect.

Sales were plus 10%.

Sales in the molecular lab increased 4% due to growth in our blood screening business. Now this was partially offset by reduced sales growth in the infectious disease segment, which grew at 1%. This was impacted by the USAID funding stop in Q1 that caused a corresponding decrease in HIV testing, which I covered last year.

Sales at or near patient care customer decrease at minus three mainly driven by the decline of our blood glucose monitoring business is minus 2% due to the market shift to continuous glucose monitoring as well as a decline in respiratory molecular point of care testing due to the late start of the 2025 respiratory season, and again back to what you heard earlier.

We are from Thomas we expect the CGM product to really be a driver for this customer in the future and we continue to invest in expanding in preparing for this.

Finally sales into pathology lab grew strongly at plus 14%, mainly driven by sales of advanced staining at plus 10% and our companion diagnostics business, which flu grew at plus 25%.

So now I'd like to show the geographic performance. That's behind these results are taking through the regional view North America. The business grew at plus 9% well ahead of market.

You saw good growth in EMEA at plus 6% again ahead of market Latin America strong growth at plus 11% now Asia Pacific again, as we discussed minus 12%.

Driven by the minus 24% decline in China.

Excluding the effect of China APAC grew at plus 4% now as you heard earlier, our consistent ambition. The diagnostics division is to grow our sales at mid to high single digits.

Given that we anticipate diminished, but continuing headwinds in China for 2026, we would set our ambition. This year at mid single digits for 2026 again are consistent ambition is to grow this business at mid to high single digits.

Now I'd like to walk you through the P&L line by line as previously mentioned sales grew at plus 2%.

Cost of sales as you heard from Alan grew at plus 7%, but this was mainly driven by that and favorable impact of the China health care pricing reforms.

Are your impact of tariffs.

And the production ramp up of our new technologies, such as CGM and sequencing and the placement of a significant number of instruments.

In 2025, and I would highlight that we saw.

Growth of some of our key platforms like our immunoassay.

Strong double digit increase in for example, our molecular workstation. The 5800 grew at over 40%. So very strong placement of instruments R&D cost o'clock decreased at minus 2%. Now. This is a result of significant and focused cost containment measures across the organization in response to China impact as mentioned.

Previously we are ensuring delivery on all our key priorities, especially our investment in the key new product areas such as C. G M dark seal their sequencing solution and luminaire Dx.

SG&A decreased by 2% again, reflecting focused cost containment measures across the organization.

This resulted in a core operating profit of approximately 2 billion Swiss francs declining at 4% at constant exchange rates, which reflects the cost control initiatives.

So now I would like to transition to some of the innovation that we launched in the last year and really specifically focus on our cobalt mass spec I 601, which as you heard from Thomas These are billion Swiss franc opportunities that we're very excited about and there are potential to really deliver grow.

To the diagnostics division so as I've mentioned before current mass spec primary relies on lab developed tests.

And lack automation are highly manual and require a highly skilled labor.

With the launch of our mass spec solution in 'twenty 'twenty four we've introduced the first fully automated IBD platform preclinical mass spec. So throughout 2025, we received CE Mark for all of our wave one menu composed of 39 analyzed spanning the key parameters using mass spec testing, including therapeutic drug monitoring steroid in hormone.

With this as well as vitamin D testing.

These comprise the majority of parameters used in routine clinical mass spec lab, and we are going to fall that with a second wave of additional parameters.

I would add that this system, which integrates with our existing serum work area platforms strengthens our leading position in the core lab.

And now I'd like to talk about some of the high medical value content that we launched last year for our serum work area, specifically, our dengue antigen tests, which received CE Mark in October.

Dengue is the most common mosquito borne viral disease globally and represents a major global health burden. It accounts for an estimated 390 million infections per year. It has shifted from being a seasonal illness to our year round risk with locally transmitted cases shifting from historical geographies, such as South America two now in euro.

In North America, diagnosing dengue it can be challenging as patients are often misdiagnosed due to overlapping conditions with other febrile illness with our lexis antigen test, we will enable healthcare systems to diagnose dengue more reliably and efficiently by providing all four dengue virus serotypes differentially diagnosed with a rapid.

Test it takes only 18 minutes.

This will add one more test to our leading immuno histochemistry platform or excuse me immuno chemistry platform, which comprises of approximately 120 a.

Different parameters.

So now I would like to move on to our customary very near and Dear to my heart.

Molecular lab and switch to discussing our cobalt BV fever assay, which we.

We received CE Mark in December sexual health diagnostics market is valued at $1 1 billion Swiss francs with a yearly growth rate of 11%.

Vaginitis as the primary growth driver within this segment showing a yearly growth rate of 26% with our cobalt B B C. B assay, we will provide a multiplex assay designed for the direct detection of bacterial vaginosis in Canada, vaginitis and expand our molecular STI offering with the addition to our STI portfolio we will.

To enable testing of the most commonly sexually transmitted infections, usually a single tube and vaginal swab in the future. We plan to continue expanding our offering in this area with home collection solutions as well as novel molecular point of care assays.

Transitioning to our point of care portfolio.

I would like to discuss our recent CE, Mark and FDA clearance with a CLIA waiver for our LIBOR to tell a panel pertussis is a highly contagious disease that causes more than 24 million estimated yearly cases, resulting in a 160000 deaths with the majority of those in children diagnosing pertussis can be particularly challenge.

<unk> as its symptoms of it often overlap with those of common colds, leading to under diagnosis are LIBOR to tell a panel offers a reliable point of care.

Solution delivering results in just 15 minutes between three four to tell of pathogens and again delivers lab like performance. This will enable health care providers to act quickly and prevent severe complications, especially in vulnerable populations such as children.

As you can see from this slide this launch we further expand our Cobalts Liang menu of lab equivalent point of care testing.

And we will continue to expand this in the future.

And with that I would like to transition to our key launches in 2026 and call out a few highlights.

Again, I would really want to emphasize that 2026 is the year that we will launch our axial Yo sequencing solution. This is a groundbreaking high throughput solution that will deliver high accuracy high throughput and flexible sequencing based on our proprietary sequencing by expansion technology. It would also again highlight.

This represents a potential blockbuster opportunity for us with sales potential and above the 1 billion Swiss franc range.

I would also like to call out the expansion of our neurology menu, including the Alexis P. Tau to one seven which is a blood based diagnostic for Alzheimer's disease, and Alexis neuro filament light chain for detection of disease activity in multiple sclerosis.

Lately, expanding our offering and neuroscience. Additionally, I would like to I would really like to particularly mentioned our TV egret test our assay to detect latent tuberculosis infection, which remains a global health care challenge and a significant commercial opportunity and I'm very convinced that we will offer a very differentiated highly competitive <unk>.

Lucian here and.

And overall this 2026 is going to be a very exciting year of launches I look forward to keeping you updated over the course of the year. Thank you and I'll hand, it to Bruno.

Thanks, Matt and with that we open our Q&A session. The first question goes to Sachin Jain from Bank of America such in place.

Hi, Matt Thanks for taking my questions cheap please.

So firstly on for volumes my guidance.

And it's a growth this year beyond the acceleration so any color on what you're assuming within the guide and perhaps I'm curious if you could just provide a bit more color on your funding comments I wonder if that doubling in 25 vessels 24 main relative to historic levels like where was that funding relative to sort of a three or four year average and any color on how that flows back to patients when we should see.

Impact of silence.

Question is on persevere, if I may.

It's a topic that I think it's come up on prior calls, but just to reiterate as we approach data.

If the study here is any hits clinically meaningful fee would you need to see a sudden hazard ratio absolutely benefits us that wording in the press release. The reasons. The question is there's been speculation since your San Antonio Cool around passing an interim nice my two questions. Thank you.

Great.

So in terms of the buys now.

I'm not going to give you specifics on the amount of money that we contributed because as you as you have heard me say many many times before our charitable giving is not in any way related to our commercial our expectations for the product. So those two things are in have to be completely separate.

I can tell you that we doubled our donations last year and that was a significant increase for us over the last couple of years as you are as you sort of alluded to them.

We do believe that 2025 represented sort of a rebase lining of the branded market in the U S and so what we are hopeful is that 2026 will now allow the underlying growth of our buys mode to actually be more visible.

And so we would expect an acceleration.

In 2022nd I don't believe we've been more specific than that.

In terms of perseverance. So you know clearly the fact that we've now seen positive data from Gary desperate in a number of important settings, both neo adjuvant and adjuvant and and and in a complex late stage population sort of underscores our belief in this molecule and that clinically it it is.

<unk> is active and it's combinable, it's tolerable, it's given us great confidence that we do have the opportunity to be really impactful for many different patients since you really become a new standard of care in hormone receptor positive breast cancer reading three though to different settings is complex and so you know thinking about how we would read through.

To persevere happily, we don't have too long to wait to actually get the answer to that question.

In terms of what would be clinically meaningful we have designed the study to yield a clinically meaningful result, and say you know generally speaking you know.

A 20% reduction would be considered clinically meaningful.

So to answer your question.

Thank you so much.

Yeah.

Okay very good then we move them nexon and the ROE would be Peter for Don.

Yeah.

From BNP, probably about Peter.

These.

Thanks Bruno.

Even though from BNP two questions I'm Troy just on obesity, we understand from us even that the eminent dates within the house.

And the market seems to set the bar at sort of being low to mid teens waitlist forget the market for a second could you just focus on rush what is the minimum target profile you are looking for some to demonstrate family.

And then secondly on P. T K you sound very confident about the probability.

Despite recent CRM elsewhere in the BT U K class you know the efficacy in the first readout from existing studying PQ man squeeze on just wanted a sense. We'll go kick the tires with you has your confidence based on our highly skewed benefit risk profile or is it more because we think the two cases of hydro that you've seen.

And the data set can be attributed to other non drug causes. Thank you yeah.

So I'm going to start with your second question first because I think we've gotten a lot of questions over the last couple of weeks about Tullow Brayton had been and read certain and read read throughs tied up right now and I think we have to be very very cautious here. If you actually read that C. R. L. It is incredibly specific to the risk benefit that was seen with Tullow Britain.

And.

Unfortunately, they had a number of failed trials. They had a number of of a highs law cases. So I think it is very difficult in an inappropriate to actually take that the language that was applied to tell of Britain had been actually put that forward on incentive right now let me be really clear because I think there have been some there's been some confusion about what we have.

Actually seen in terms of highest law cases, four five right now and we had two cases of elevated liver enzymes with deliver then which was what put us on clinical hold with the FDA.

Both of those cases, we're in fine hands, one which currently is a study that's still remains blinded when we looked at those two cases only one case was deemed by the F. D. A to be a highs law case. The other one was confounded due to alcohol use by the patients.

And so right now in Senate Britain. It we have only one case and it is and it isn't fan hence one so we are sort of blinded to any more detail.

It's also really important to note that since we put liver monitoring in place in the clinical trials, we have not seen any more.

Any more cases, and so I think we feel very good about the overall benefit risk profile that we have with tenet Brittany, particularly when you consider the other half of that coin, which is the benefit when you look at the phase two trials for Senate Britain have you saw a significant amount of clinical benefit to patients and.

Is it the data that we've seen are very consistent and so I think when you look at that very high efficacy with a with a very you know what looks to be very manageable safety profile. I think we're just in it and in a totally different situation than what you saw with calibrate. It. So hopefully that kind of provides a little bit more.

A little bit more perspective, there so in terms of petrol and tied so as a mono therapy. We believes that petrol untied holds the potential to be a foundational therapy for weight management and we are looking forward to being able to deliver a weight loss at the vast majority of people are actually looking for which is something more in that sort of 10.

Twentyish percent with the potential to be a much more improved tolerability profile compared to the G. L. P classes as well as a patient you know it's the.

Better patient experience in terms of penetration quality of weight loss et cetera. So obviously, we don't again happily have long to wait we will see that we will see that data. Soon you mentioned the data being in house. We are we remain blinded to that data so.

So we have not seen it but we do expect to see it very soon.

Does this answer your questions.

Thanks Breanna.

And we move on and then next one would be Simon Baker from retro and Simon.

Thanks, very much Bruno thank.

Taking the questions two from me. Please firstly just continuing on.

On Pete's question about.

About <unk>.

I just wonder if you could if you could give us similar to about how we should be thinking about the relative tolerability profile.

Of.

Bush's awkwardness are ahead of the actions data.

And how do you see.

In light of that kind of bridges being positioned relative to octopus.

And then secondly, a question for Matt.

Well since you unveiled to us.

You sequencing offering I'm just wondering if you could update us on the market feedback you've had in terms of levels of demand and where that demand is coming from whether it's smaller scale or larger scale applications. When the bus. Thanks so much.

Gotta go first I would be delighted to go first and I'll be happy Super before Wow, So yeah, and I would maybe give a plug for our diode day in May, which we'll talk quite a bit more about this and Bruno well will mention that at the close maybe I'll just say that first but yeah, we've seen a high level of demand for this.

Winter I would say in a more than we had originally anticipated ahead of launch.

We are already starting.

Commercial activities with select customers and the feedback from our early evaluate or has been extremely positive. So when you talk about applications. We're really seeing interest in a broad variety of applications from translational such as single cell, but then onto more focused.

Focused clinical applications, such as whole genome sequencing in germline, so what really seen as the potential of an instrument with that kind of flexibility throughput and accuracy and a dual assay format with the longest reads of simplex as well as the very high accuracy duplex format to have a broad applicability really across the spectrum of sequel.

Applications and I think we're very confident in the potential for this technology as well as the launch.

Does that answer your question.

Salman perfect, yes, great.

So when.

When we think about where fund had a where Senate Britain obsess I mean, we believe that it has best in class potential and together with the OCA vis OCA met some cut.

And potentially you know further on down the line OCA is high concentration. We believe ultimately we are going to have a range of highly efficacious and very tolerable therapies that meet every patient with M S exactly where they're at.

Right now 30% of patients are on a less efficacious oral therapy, and so that's sort of an easy place to imagine Center Britain, starting but I think ultimately we.

We believe that this is the combination of these two therapies gives us the opportunity to really sort of revolutionize the entire patient journey for Ms patients and I think we what we're feeling.

Confident about our ability to do that.

Alright, thanks, so much sorry, I would just sit back them to meet some reason that concept.

Okay. Thanks Ana.

Next questions go to Matthew Weston from UBS.

Yeah.

Hopefully you can hear me.

Thank you for taking the questions. The first one on <unk>.

Two industrial Teresa is there's a lot of debate about how the commercial potential in the adjuvant setting could be impacted by the data from et cetera.

You give us your thoughts as to whether or not you see adjuvant is independent of that frontline metastatic result.

And also there's a lot of debates about the peak sales potential of jewelry restaurants. So when do we when should we expect to hear what rush thinks the potential of this medicine is.

And then secondly, if I can just pick up on the Biosimilar erosion.

So Q2 Q3 of last year, you made a number of comments about.

No delays to the entry of Zola I'm now similar comments about potential delays to the entry of Biosimilars Jets are clearly there are multiple patents. So you could do deals with biosimilar companies, but do you think investors should get used to a more gradual erosion of some of these biosimilars at the beginning of generic entry.

Free or should we still continue to expect to see like a minus 40% has been kind of the underlying trends so far when we actually see biosimilars and to the market.

So I'll I'll take thanks, Matthew for your questions I'll take your second one first and I have a very definitive answer for you which is that it absolutely depends so it depends on the therapy. It depends on the part of the World I mean I think it's this is one of those things where biosimilar impact is is not a one size fits all so you know in some part.

It's a the world with some therapies you are going to see an immediate decline with some others like xolair or we just do expect that to be a smidge more sticky because youre dealing ultimately it was a very allergic patient.

And so physicians might be a little bit more tentative about switching so quickly.

And so I think this is one of those areas, where we are constantly monitoring the environment, we're constantly talking to treating physicians to get a sense of how they may think about the utilization of Biosimilars and we gave to you are our best knowledge of how we believe those erosion curves will happen.

But it's very difficult to give you one answer because I think it is actually quite variable again by therapeutic area and by geographic area.

When it comes to carry restaurant. So this this market is somewhere between 20 and 30.

Billion dollar opportunity.

M. Adjuvant is about two thirds of of that between our initiation and maintenance therapy, and we do think that adjuvant. In first line is is pretty separate them and we think that Gary <unk> has the opportunity as we said to really be establishing itself as a new standard of care. When are you going to get a better read through from that.

Q1 is a very data rich care. So in the first half is a very data rich time for us we're in the process of updating them updating on our own assumptions and as soon as we have a clear read through we will share that with you.

Maybe just to answer your question on project as well because you have this question. So we don't expect the Biosimilar Fujitsu until 28 in the U S and 27 in the correct.

Just to clarify that.

Matthew.

Question, So that's perfect on Q.

Hum.

The next one would be <unk> from Barclays.

Two students Barclays. Thanks for taking questions.

Questions. Please.

Okay.

Okay.

The labor to the original target.

If somebody wants to be Q2.

It's a little bit slower.

Could you be getting a few more than denim and could that actually help the car, which is where they can send some people aren't.

And also it has something to do with study of this size, it's not even about 100%.

October.

We communicated that.

It sounds like Youre funding.

The touch screen.

On page <unk>.

It's too late.

Yeah.

And then Neil Boehm, Brazil.

You sound very consistent.

Great.

And so literally.

So in terms of affordability.

The general release.

Safety data.

Related to that.

To be sure.

Hey side effects, we have to think about.

Cleveland.

Turning it to some of the older vis so you've got the advantage of oral but could you also have liver monitoring or something like that could not be a barrier to becoming a pretty big how would you think about it.

Right Okay. So.

Well start with the second question first so we.

We intend to assess the safety of Senate Britain. It when we have the all of the studies read out and we looked at when we look at the pooled safety. So obviously, we only have two of the three studies. So we need to wait a little bit in order to be able to step back and look at that on the data that we've seen so far we haven't seen anything that is different than <unk>.

What you would see in the background rate of the overall and Thats population in terms of liver monitoring as is typical when you are when you get your label usually for things like monitoring you get what you studied in your label. So we would anticipate that we would have the same liver monitoring in our label that we had in our clinical trial and again I think when you look at.

The efficacy and the and the risk benefit profile that Fanapt route and it has I think there's still this is going to this is going to be a meaningful medicine.

M S. So more to come as we get the fan hence one data.

Person Dara just to be really clear the timing on that has not changed we have consistently been messaging. The first half maybe first half of.

Of this year and that has not changed so that that is remaining Ah Ah that is remaining consistent.

And again, we do plan to file the lid Dara data first we get the the Burma data I believe.

The sub study data come since that also in Q1 Guy someone's going to have to remind me of that.

And then the ribose study, which is a 200 patient subset is just kicking off so that will come later on so those databases that clearly are sitting there.

In public.

The filing is Ah is going in and doing it looks.

Looks like end of 'twenty.

Upside is.

Okay.

All questions and answers.

Okay.

Then.

Excellent I shall read a couple of them.

Absolutely.

Hi, Thanks for taking my question. So you would have asked us any approval risk and I guess I'll just touched on it but what is underscoring our confidence in the commercial potential what's the initial feedback from the physician community bank can be seen all rules that liver tox launch how you see just plenty of people, which had struggled to reach 1 billion just shy I guess why.

I sent a pretty Smith different and how are you viewing breath from Novartis is rarely approve snip in RMR stake. Thank you Candace and they've had no signs of liver Tox I saw.

And then the second one system has a favorite until they've been touched on but how confident are you that you have enough patients in the trial to hit Stat, Sig and how should we think about the possible study and the potential read across to pass Sarah. Thank you.

Right.

So let's start with Senate Britain. It. So obviously the data have not yet been presented so the P. P. M. S stayed out goes to App trends shortly and then the RMS data will be packaged together and when we have done has one as well.

That having been said, we've obviously shared it with with those physicians who are part of the trial and I think people have been really impressed with the data that we've seen in in particular people were really impressed with the phase II data that we've seen so what we're talking about is the ability to get OCA of us.

Like efficacy in an oral treatment and for many patients for many many different reasons, that's a very attractive option. So you know.

Again, I think in this market a lot of it comes down to the overall efficacy that.

And that we're able to deliver them and based on the phase two data. We believe we have a highly efficacious molecule on our hands in terms of the Novartis data I mean, it's important to remember we haven't really seen anything and MFS from Novartis. Yet. This is a dose that I think is about four times higher than the existing dose.

They had a had sort of a second mover advantage or they started their trial with liver monitoring. So you know I think it's very difficult to compare because we just really haven't seen anything we have first mover advantage here, we had robust phase two data and.

Yeah, I mean, I think we are at it.

It's very difficult to say anything until we actually see data. It's also I think important to remember that Senate Britain. It as a non covalent molecule and in a chronic indication that non covalent and see really matters because it means that even though you're taking it.

Even though you're taking it chronically if you need to stop for whatever reason it does leave your system more quickly and I think that's that really in a chronic care environment is a benefit.

So in terms of read through for persevere, our you know.

It's clear when when breast cancer is dependent on the endocrine receptor for viability geared restaurant can perform very well and we've seen that in a number of settings. So all of these patients are by definition dependent on the ear signaling and it's worked really well here. So clearly on the frontline the likelihood that a successful.

Hasn't hasn't gone down.

And we.

We should always be really cautious with cross trial comparisons and so I think we are you know.

Again as I mentioned the benefit is we don't really have along the way. So we'll we'll know really soon.

Oh, and yes, persevere is designed to show improvement over Palo plus I'll, let Russell.

Sorry for all the questions answered.

Yes. Thank you.

Yeah.

And then Exxon into Qs, Richard Vasa from J P. Morgan.

Yeah.

Thanks, Brian.

Thanks very much two questions. Please first question just to go to the diagnostics for a little bit.

Margins, obviously hit by a by a ramp up of <unk>.

Mass spec sequencing on the machine placements could you give us a bit of color on how to think about the margins from here those placements seem likely to continue as you ramp those those two businesses up so how should we think about 'twenty six and then and then the improvement in the margins from that and then second question back to pharma just gone.

Back to Verbalize my.

Thanks for the comments on the foundations could we got a little bit further out and think about the future competition potentially from less frequently dosed Ah injectable products. Thank God killer has one half yearly Ah how how you think about that sort of competition and also closer to today the biosimilars in a really stellar.

To come they're having some impact in in in Europe as far as we can see say just watch what's the thoughts are globally U S. Europe on Biosimilars from Eylea.

All right thanks very much.

Yeah.

Maybe I'll go ahead and disconnect.

Thank you.

So maybe starting with diagnostics that we talked about a couple of effects. There is the new technologies. There is the the tariffs of which Alan said, we had half a year and we'll have a full year. This year, but the biggest effect on on what hit US last year on the margin was really the China effect and as you heard from Thomas we expect to see this meaningfully diminished this year.

2027, again, we expect a decline, but it'll be small enough that it won't really be a meaningful and then we expect to see a recovery.

In terms of specific ambition on margin. This year I think I would refer you back to the to the group a position that Allen a reader that Alan mentioned earlier, but I would say are consistent ambition is to grow profit faster than sales and that as you know once we really get ourselves through the headwinds. This year that is our ambition going forward.

And it's also our continuous ambition to improve the margin in diagnostics, that's something that is a.

Our goal for the entire organization, what I would call. It though in 2025 as you at our second largest market with a 25% reduction. So obviously there was an impact but that's something that you can see with our discipline on the cost line.

You can also expect to see continue again in 2026, but we expect the gradual wash out of that.

Anything you would add to that Alan.

Well I for 26, I think well we'd be we expect kind of a stabilization I think that's a little bit of time, but as you look give us additional information. So I would I would maybe just refer to what Alan said, we our goal really this year is going to be that we stabilize the margin.

And I think on a group level, you've seen that our intention is to expand margin.

In 2026, and where that sits in the past still holds which is also going forwards we will at least keep margins stable.

Also for the coming years.

Perfect. So to answer your question.

Thanks.

That's great.

First just to start by talking about the buys now so I mean, the buys mall is a highly efficacious therapy with a very well defined safety profile, where patients and physicians do you have a lot of good experience in extending doses.

And so and it is designed to do just that when.

When you when you look at you asked specifically about ocular I mean this this drug is going into phase three with a very small.

Safety database and really no known no no known data on long term safety and when you talk about something that's going to be used into ocularly them over a long period of time I think you know long term safety is incredibly important and I think it's very difficult to think about you know how the.

You know how something like that is a threat to something that has such good efficacy such good safety.

And while you do actually have the ability to to extend doses. So I think from a from.

From a future competition perspective, you know just just like and in other disease areas sort of the bar is high here to unseat a bias now.

And you had one other question.

Oh biosimilars, so so far you know.

What we see is that the Eylea biosimilars are taking from Eylea.

And so for those patients who are really benefiting from a new and novel treatment by buys now there there were just less impacted so yeah and I think we saw lucentis take from the centers, we're seeing eylea biosimilars take from Eylea, and we're seeing high dose eylea take from low dose eylea. So theres a lot of trading within that space, but I think for new patients.

Who are going on therapy physicians are picking the best available therapy out there available to them and that is the bias now okay and on the ophthalmology I would like to add that we have an amazing pipeline in ophthalmology. So when you look at all the different validated targets I think we're the only company that actually has a different level.

It's in house and so if you look at our pipeline, we have tri specifics tetra specifics do the fabs et cetera. So.

If I look at the ophthalmology pipeline I think the one that's going to succeed.

Succeed.

You know it surpassing the buys moves then hopefully us.

Very good.

Richard.

Perfect everyone. Thank you very much very helpful. Thanks for that.

And nexon in the Q S J.

James quickly from Goldman Sachs.

Thanks, Bruno hopefully you can hear me.

Just a couple of quick questions from my side leftovers. So firstly again on dirt I shouldn't and revisiting them do their work.

It's the kind of gut reaction been from from your side and so some of the cargos. We spoke so had been a little bit more cautious than the present through it youll subsidies event.

Given the more limited follow up versus the CDK four six class.

It could impact.

Jerry just a trajectory of course assuming approval.

Respectful stepwise ramp or.

Oh.

Most of that was as more data comes or what.

Or does your feedbacks suggest the potential for Boston more optimistic ramp.

Restaurants so.

The first one second one more financial question so.

Underlying pharma growth has been pretty strong in recent news driving operating leverage so how is rough balancing R&D investment with profitability, but how long can R&D expenses stay flat.

This all seem to show you that Russia is a strong ability to reallocate costs in R&D, but how long how long can this go on to support our pricing leverage. Thank you.

I mean, I think what we're hearing from the Kols community regarding where they would use the Dara is is pretty bullish I mean, I think what we hear from the Madera population is 55% of the.

Adjuvant breast cancer population, that's 10% more than what we saw in the Natalie trials. So you know I think you are really seeing physicians believe that this could have very broad applicability in their practice and so I think that what that's what that's what leads us to be fairly fairly bullish about the opportunity there was a 74% overlap with the pop.

<unk> and Natalie and monarchy in so I think where we are very yeah. I think we're very confident that we have something on our hands here that is quite a game changer based on the data that we've seen.

Me answer the second question, but first something to add on jewelry. This trend I mean, you look at the hazard ratio of <unk> seven.

You can see that that's I would say highly competitive to also some of the CDK four six trials that you've seen at vinyl, but what you have on top of that is the tolerability.

If you look at CDK four six you had for quite a high amount of patients that actually stopped using it.

Simply because they cannot take the tolerability. So I think these are all the right arguments for so that's to be used.

So I do believe that a.

Pick up will be strong unfortunately, it wasn't at the Congress in San Antonio, but it hurt there wasn't even a standing ovation from a from a.

The conditions there than.

And then the second question on R&D.

Hum.

So we're working very hard to be a high performing very cost efficient organization and there are still opportunities in my view to continue to work on that AI by the way plays a big role in that we're using AI throughout the entire development process, where we wanted to on the one that speed up using AI, but also reduce costs.

Doing that.

Regarding R&D expenses.

Also for 'twenty 'twenty six.

I would say it would be broadly flat again really focusing very hard on.

Making sure that we put.

Put the money to work in the best possible way for the sake of patients in our company and for our investors.

And as you all goes back to the margin point that you've made.

I hope I made before which is that this is you know it's cleared up with when you fix expand margin and as previously always say, it's at least stable and disciplined for the long term.

James.

Thank you very much.

Okay.

And.

We move on to Graham Parry from Citi.

Jim.

Okay.

Gotcha.

One of them the Dara thanks for clarifying the filing time lines being Q1, just wondered if you could comment on whether you expect priority review, which use approach.

Rajeev voucher or not.

And when exactly do you think you would expect to see the Rainbow combos that subsidy data 200 patients.

How long does it take to recruit until we see something by the end of this year is that a next year event.

And then on.

The business.

Can you just confirm how important you think confirmed disability progression is this is annualized relapse rate reduction.

In showing a risk benefit profile and differentiation. This is <unk> to the regulator.

Given the it's a very brain penetrant molecule and how soon you see therefore, the ability to work on disability progression, whereas CD 20000.

Oh geez.

You're still on clinical hold with FCA. So does that have to be listed before you can actually file or receive approval and what are the steps to doing that thank you.

Yeah.

Yeah. Okay. So we expect to see about a sub study by the end of the year, we would expect a rigor in 2020 seven that that that is really only starting now so we've got a we've got a little time, that's 100 patients.

And the Obama arm.

And in <unk>, it's 200 patients.

The F D. A hold will be addressed as part of the planned feni filings, but we've obviously been in consistent conversation.

With the agency over time, so there that we've been in very close very close contact I won't comment on our filing strategy only to say that we plan to we plan to bring <unk> to patients as quickly as possible.

And for in terms of.

Confirmed disability progression I think we are at the.

The annualized relapse rate is is also a very good is also a very good end point here.

And we are confident that that is giving us what we need in order to proceed.

Yeah.

Graeme any additional questions or.

Oh good.

Then we will move on.

And I hand over to Raj Kumar from HSBC.

Right.

Hi, there.

Two questions if I may 1st on.

On.

The C D E P T.

Thanks for clarifying discontinuation rate in the high schools with similar to the overall group.

You also mentioned that you could consider a flexible dosing.

In phase III, because as an option.

Could you give us some color on how you're thinking about safety.

Uh-huh program.

Flexible tubing.

Or an active comparator Kobe, something you might consider or is it a.

At the moment too early to comment on that.

Second just on two different a quick follow up.

You know who.

You highlighted the overall Tam this class is targeting to be quite a large number.

You are filing with a few from both Super outdated I was about to read so just in terms of the market segmentation.

How much of the market you think has been risk.

D. This to some extent and how much are we still depend on the data in your assessment of the market would be.

Very much appreciated and because I'm, an analyst and I cannot count.

The third question would be just on clarification on the buy small.

Appreciate the working capital impact of gone up and up.

Sort of reflects a very strong December so.

You should reconsider the exit rate of December.

Close the indication of how you're thinking about growth in 2020 fixed or should be.

<expletive> and overall slower growth rate going forward on goodbye smoke.

Okay.

So I would just go back to my earlier comments for vote by small we expect to see an acceleration of growth in 2026, so more to come on that in terms of the dosing for C. T 388. So what we have disclosed is C. T 388 it.

It will be it minister once a week and we're aiming to develop it at three maintenance doses are we are not disclosing at this time the details of that dosing strategy.

Just to avoid any.

Any misunderstanding, we have not indicated that we will be doing flexible dosing within the trial, so but right now the details of that phase III design.

Design that specifically have not been have not been disclosed and then in terms of gear desperate in the market segmentation. So it you know and how much do we feel like has been derisked well two thirds of the market is adjuvant and we have a positive adjuvant trial.

So I mean, I think a significant portion of the.

Oh, we have a significant portion of the market has been derisked.

Okay.

Thank you very much.

Okay then.

Next question from Michael Washington.

From Jefferies.

Thank you Bruno a question from Matt Please.

Abbott said last week that the Chinese may be presumed EVP for core lab oncology just wondering whether.

You've heard that.

That may or may not be reflected in your outlook on the margin commentary you made earlier.

And then sorry, Teresa just going back to the base of just your comment about 2025 in the U S being a reset.

Q4 was still soft it didnt really improve upon Q3 sequentially. So when you. When you say you think that's that's now stabilized and it can grow from here just wondering how you look at the Q4 versus Q3 Q3 dynamic in the U S. Thank you.

Okay, three Wow [laughter] [laughter].

So.

What I would first start off by saying is as you may know there was GBP for core lab oncology reagents last year and so.

That was what you see are China effect last year significantly.

<unk> represented a decrease in our core lab oncology really reagents, which were down about 50%. So some of that effect is still pulling through this year, but.

I can't speak for what we said on that call but.

We are seeing the effect of the V BP last year and the national reimbursement reduction So we don't anticipate.

Additional core lab oncology BBB this year.

So it it and thinking about.

The buys now.

Q4, So 2025, we saw a big reset in the branded market in.

In our in the U S right with the closure of the copay foundations fewer patients were put on branded drugs more patients were put on avastin and in Biosimilars and you saw a big just sort of reset and how many new patients continuing patients were actually going on a branded therapy and that constricted.

The market by about 15% that constriction went all the way through Q4 because.

Because normally when donations are given or grants or given their get in four years' worth of therapy.

What's happening right now in.

In the oncology World is something called the Blizzard, it's where every retinal specialists in the U S goes and re verifies the benefits for every single one of their patients and it's at that point in time that you know patients actually determine what will they be continuing on their current medication will they be switching etcetera, and so you know over the course of the.

Next couple of months I think we're going to get a real sense of what is the trajectory of the branded market going to look like in in 'twenty 'twenty six but.

Because that underlying base effect of 'twenty 'twenty four is now washout, you should be able to see the actual branded growth of people going on to new therapies actually come through.

So I think there's a reason why we didn't see Q4 look any different than what the rest of the year looked like I think we had sort of hopes that we might see we might see some early signs of recovery, but I think those signs of recovery really are going to come become a little bit more evident as we get towards towards the end of Q1, So Michael I hope that addresses your question.

I mean, we the Cola assistance Oh the.

Foundations they were separate right so nothing that.

In terms of influence with what we can say is in general.

Our our nation was towards the end of Q4, and then again, we don't we don't we don't link those two things it.

It is interesting to know, though that in Q4, we did see a 4% growth. So we saw a.

We went over call it quarter over quarter growth, we did see a 4% growth we did see a little bit of an uptick.

Michael any follow on.

If not then.

I want to hand over to Pelekunu from Cowen <unk> co.

Uh huh.

Yeah.

Thanks, Bruno this is Paul on for Steve Scala too.

Two questions. Please what feedback have you heard from U S oncologists and how they plan to initially use Gary district in the adjuvant setting.

And secondly, how does the change in Xolair Biosimilar entry from end of 2026, two before November 2026 coming out was this a change in the settlement with generic manufacturers. Thank you.

Yeah.

So.

With regards to solar I think we have long said sort of second half of 2026 is when we expected the first biosimilars to come in for the U S. I don't actually think that that's the change.

Hum.

<unk> November was just related to IRI.

We need to have a bias to have a place.

Payer in the market before the first of November.

We cannot get negotiated that it that is correct. That's my my reference to the first of November was purely around CMS guidance that says if you have a marketed biosimilar by November. One 2026, then you will be removed from the negotiated basket. So that's where that date comes from but we've always said second half of 'twenty 'twenty sexual.

We would expect to have a biosimilar in the market.

And then feedback from oncologists on on where they intend to use for adjuvant I mean again just to continue to reiterate them in a 55% of the adjuvant population was covered by the the Dara trial and so I think you see a high degree.

We have confidence in and oncologists to use in a very significant portion of their patience and again you know with what we saw here was a very a very efficacious are seemingly combinable, and and and and well tolerated therapy that I think has the opportunity to.

To really become a new standard of care in this setting so what we're hearing from oncologists in general is that there they're pretty excited to have this in their hands and we're excited to get it to them.

Okay.

Paul Let me answer all of your questions.

Thank you.

Mhm.

Then.

Next one would be Justin Smith from Bernstein Justin.

Thanks.

Two please.

Hum.

<unk> 007, just wondering if you could share some thoughts on win.

So you design the head to head versus the Labor P.

Okay.

Second one prognostics not just wondered if you could talk a little bit about CGM.

The fingerprint recalibration will be removed.

Many of them.

Wow for a new territory.

[laughter] so.

I wanted to first thank Theresa for generosity, but.

So David your question on auto calibration, which is the comparison of the CGM device with a blood glucose Lance it what.

What we are planning to do is have that March happened. This year, I won't say exactly which quarter, but that is a an improvement that we expect to deliver this year.

Okay.

With regards to next double the seven we would expect a we would expect those trials to start in Q1 Q2 with a with a clinical.

Clinical trials dot Gov entries that around that time frame.

And again these are two studies, one head to head and in one versus a factor of one hand labor.

Yeah.

Justin.

All questions answer.

Yeah, great. Thank you.

And I Wouldnt, maybe retailer allowances of three questions, which I got from.

Luisa Hector she had to drop off and I promise I will go freedom that.

There is one question on Oculus Lenovo, so distillate of naive versus switch patients that we are capturing and what does the targets which rate for 2026 and at peak.

Hum.

What I think we have been communicating that we have 2 billion in incremental sales for our crews, but this is true incremental sales on top on top basically rewards.

Revenues coming from switching so we have not yet provided a detailed outlook on watch.

The ratio of IV to subcutaneous would be at around 2009, we might do that at a later point in time.

Then the second question I found interesting on the pipeline 66 enemies now on the pipeline is right sized and what we have seen now with the turnover in the fourth quarter with four molecules added five going out so five edit foregoing Alex is this an hour.

Is it still a cleansing ongoing off the pipeline. This does nowadays the regular run rate in the turnover or would we target a more enemies overall.

Yeah, I mean, I can answer that question.

So overall you know you apply the bar not only once you play apply the board constantly based on data that you generate but also data that you get from the outside.

So clearly I think we are at a point, where we'll continue to bring in additional enemies. We have actually when you look at the very early stage of our research organization, we've actually doubled the amount of molecules moving ahead. There. So we do believe that will continue to expand on the minds of enemies.

That we have enough before you'd be onto the 66, but just kind of I would say privatization is just something that you have to do constantly based on just availability of data.

And then the final question here would be on capital allocation, giving you positive pipeline progress pharma deals with the U S administration on which competitor developments and obesity are there any changes to your M&A objectives, and the R&D investment plans.

No I can I can say there is no fundamental change I think what we have really shown over the last couple of years that we've been very disciplined very disciplined in terms of financials, but also in terms of.

Really screening the market for Ah interesting molecules with good data.

If you look at the amount of money that we spend compared to our other companies in the kind of pipeline. We felt are doing that I think we've been pretty efficient and our intention is to continue to the same and just continue to be quite disciplined on.

That's the.

The good thing is we are not in a situation, where we have a huge patent cliff right. So we're not illustration, where we have to do a late stage deals which are very closely.

We are in a very good position when it comes to a late stage pipeline, but obviously I mean, if you look at the amount of innovation that's ongoing outside.

If you look at what's happening in China, we.

We need to continue to screen the market and look at everything Thats out there.

I mean I looked at the statistic.

For about 1002 companies that we look at with the one one deal.

And I think that's also what I expect of our organization that we know exactly what's going on outside so that we can make data driven decisions.

I think with that actually move out at the end of our Q&A session. Let me just remind you of the two upcoming IR events, we already have flagged I assume there might even be more of this on February 9th our neurology call. If we were to cover up the a P. P. M S data for kind of broken up.

Rented at actress and then on May 12, we again will have our diagnostic day as a life event in London, where we will take you through the entire portfolio and highlight the C. I think will be SPX sequencing as we all know in the look global launch face I think there is the next steps to come.

But our pricing and so on and so I think it will be an exciting event and with that I hand over to Thomas for the final remarks. Thank you very much blue and a few things also to the team.

Quite exciting times I mean, if I see all the discussions that we've had as a team over the last three years and the progress. We made I think it's significant and it's not only that it's also a lot of fun because we get to talk about what we like to talk about was the science, which is about progress for patients and with people.

And then myself, who like mess also we can talk a lot about financials. So I think theres a lot of good things that are going on and we have a good momentum both on financials and pipeline. So very proud of the team.

And I do believe you know we've.

Oh, it's done what we said, we're going to do and you'll continue to see that going forward. We continue to move with focus we continue to move with speed and as always you can count on us because we will deliver.

Browse all earnings call transcripts

Full Year 2025 Roche Holding AG Earnings Call

Demo

Roche

Earnings

Full Year 2025 Roche Holding AG Earnings Call

RHHBY

Thursday, January 29th, 2026 at 12:30 PM

Transcript

No Transcript Available

No transcript data is available for this event yet. Transcripts typically become available shortly after an earnings call ends.

Want AI-powered analysis? Try AllMind →

Earnings analysis guides

Methods for extracting KPIs and checking source support when reviewing an earnings call.

Browse all earnings calls